SAB Biotherapeutics completes GLP-tox study for SAB-142 T1D therapeutic; IND filing within 12 months

SAB Biotherapeutics, Inc.

SAB-142 well tolerated in GLP-tox study; dose-dependent pharmacologic effect confirmed.
First fully-human anti-thymocyte hpAB for type 1 diabetes; may avoid immune reactions seen with animal-derived antibodies.
SAB to submit IND filing within approximately 12 months.
SAB-142 dosed at 1, 5, and 10 mg/kg; prolonged lymphodepletion suggests potential for optimized dosing.
Potential to delay onset/progression of type 1 diabetes and other T-cell mediated autoimmune diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.